Freedom From a Detectable Ultrasensitive Prostate-specific Antigen at Two Years After Radical Prostatectomy Predicts a Favorable Clinical Outcome: Analysis of the SEARCH Database

Urology

Volumn 75, Issue 2, 2010, Pages 439-444

  Chang, Steven L ^a,b   Freedland, Stephen J ^c,d   Terris, Martha K ^e,f   Aronson, William J ^e,g   Kane, Christopher J ^h   Amling, Christopher L ⁱ   Presti Jr , Joseph C ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UCLA MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DATA BASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 75349092531     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.089     Document Type: Article

References (23)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
2. Ward J.F., Blute M.L., Slezak J., et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872-1876
3. Thompson I.M., Tangen C.M., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
4. Trock B.J., Han M., Freedland S., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769
5. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
6. Tollefson M.K., Slezak J.M., Leibovich B.C., et al. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc 82 (2007) 422-427
7. Freedland S., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
8. Vessella R.L. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem 39 (1993) 2035-2039
9. Nakamura M., Hasumi H., Miyoshi Y., et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 12 (2005) 1050-1054
10. Shen S., Lepor H., Yaffee R., et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173 (2005) 777-780
11. Shimizu F., Matsuyama Y., Tominaga T., et al. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Urol Int 79 (2007) 356-360
12. Taylor J., Koff S., Dauser D., et al. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 98 (2006) 540-543
13. Teeter A., Presti J., Aronson W., et al. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT?. A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int (2009) In press
14. Diamandis E.P., and Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 24 (1997) 275-282
15. Henttu P., and Vihko P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun 160 (1989) 903-910
16. Ellis W.J., Vessella R.L., Noteboom J.L., et al. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 50 (1997) 573-579
17. Junker R., Brandt B., Semjonow A., et al. The biologic lower detection limit of six ultrasensitive PSA assays. Anticancer Res 19 (1999) 2625-2628
18. Denham J.W., Steigler A., Wilcox C., et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 9 (2008) 1058-1068
19. Chan D.W., Kelley C.A., Ratliff T.L., et al. Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. Clin Chem 45 (1999) 1863-1865
20. Haese A., Dworschack R.T., Piccoli S.P., et al. Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems. Clin Chem 48 (2002) 944-947
21. Morris D.L., Dillon P.W., Very D.L., et al. Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum. J Clin Lab Anal 12 (1998) 65-74
22. Venkitaraman R., Norman A., Iqbal J., et al. Clinical implications of introducing a new PSA assay. Int Urol Nephrol 40 (2008) 657-661
23. Valicenti R.K., DeSilvio M., Hanks G.E., et al. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 66 (2006) 1064-1071